Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
509
datasets available to search
ShareScore release 0.9.0
Dataset results
509 results for “Hepatitis C Virus”
Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy
ClinicalTrials.gov study NCT03903185. IPD Sharing: NO. Countries: 1. Publications: 2.
A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
ClinicalTrials.gov study NCT02510300. IPD Sharing: YES. Countries: 9. Publications: 1.
Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan
ClinicalTrials.gov study NCT00543244. IPD Sharing: Not stated. Countries: 2. Publications: 24.
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
ClinicalTrials.gov study NCT01447680. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Reducing Hepatitis C Virus (HCV)/Human Immunodeficient Virus (HIV) Risk Behaviors Among Injection Drug Users in China
ClinicalTrials.gov study NCT01647191. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Hepatitis C Virus (HCV) Positive Liver Grafts in HCV Negative Recipients
ClinicalTrials.gov study NCT03650920. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
ClinicalTrials.gov study NCT01685203. IPD Sharing: Not stated. Countries: 0. Publications: 2.
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection
ClinicalTrials.gov study NCT00353418. IPD Sharing: Not stated. Countries: 0. Publications: 1.
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
ClinicalTrials.gov study NCT02692703. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus
ClinicalTrials.gov study NCT03540212. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection
ClinicalTrials.gov study NCT01560468. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medicat
ClinicalTrials.gov study NCT01455090. IPD Sharing: Not stated. Countries: 3. Publications: 2.
Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients
ClinicalTrials.gov study NCT03249194. IPD Sharing: Not stated. Countries: 1. Publications: 1.
P300 in Early Cognitive Impairment in Hepatitis C Virus
ClinicalTrials.gov study NCT04389268. IPD Sharing: NO. Countries: 1. Publications: 5.
Data from: Evidence that hepatitis C virus genome partly controls infection outcome
Open the record for dataset details and reuse information.
Data from: The burden of Hepatitis C virus infection in Punjab, India: a population-based serosurvey
Open the record for dataset details and reuse information.
Data from: Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineage
Open the record for dataset details and reuse information.
New incidence or recurrence hepatocellular carcinoma (HCC) in genotype 4 hepatitis C virus treated with sofosbuvir/daclatasvir with or without ribavirin
Open the record for dataset details and reuse information.
Data from: miR-122, small RNA annealing and sequence mutations alter the predicted structure of the Hepatitis C virus 5′ UTR RNA to stabilize and promote viral RNA accumulation
Annealing of the liver-specific microRNA, miR-122, to the Hepatitis C virus (HCV) 5′ UTR is required for efficient virus replication. By using siRNAs to pressure escape mutations, 30 replication-competent HCV genomes having nucleotide changes in the conserved 5′ untranslated region (UTR) were identified. In silico analysis predicted that miR-122 annealing induces canonical HCV genomic 5′ UTR RNA folding, and mutant 5′ UTR sequences that promoted miR-122-independent HCV replication favored the formation of the canonical RNA structure, even in the absence of miR-122. Additionally, some mutant viruses adapted to use the siRNA as a miR-122-mimic. We further demonstrate that small RNAs that anneal with perfect complementarity to the 5′ UTR stabilize and promote HCV genome accumulation. Thus, HCV genome stabilization and life-cycle promotion does not require the specific annealing pattern demonstrated for miR-122 nor 5′ end annealing or 3′ overhanging nucleotides. Replication promotion by perfect-match siRNAs was observed in Ago2 knockout cells revealing that other Ago isoforms can support HCV replication. At last, we present a model for miR-122 promotion of the HCV life cycle in which miRNA annealing to the 5′ UTR, in conjunction with any Ago isoform, modifies the 5′ UTR structure to stabilize the viral genome and promote HCV RNA accumulation.
Prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa
<p><span><span><b>Background</b> </span></span></p> <p><span><span>Due to its invasive procedure patients on hemodialysis (HD) are at high risk of infections. Infections acquired in dialysis units can prolong hospitalization date and/or prolong illness in patients, and increase treatment cost. There are no adequate data on the prevalence of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections in HD patients. Therefore, this study aimed to estimate the pooled prevalence and associated factors of HBV and HCV infections among HD patients in Africa.</span></span></p> <p><span><span><b>Method</b></span></span></p> <p><span><span>The databases PubMed, Medline, EMBASE, Cochrane library, web of science, African Journals Online, Science Direct, and Google Scholar were searched to identify relevant studies. The review was performed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data were extracted independently by two authors and analyzed using STATA 11. A random-effect model was fitted to estimate the pooled prevalence with their 95% confidence interval. To detect publication bias funnel plots analysis and Egger weighted regression tests were done.</span></span></p> <p><span><span><b>Results</b></span></span></p> <p><span><span>The overall pooled prevalence of HBV and HCV infection among HD patients in Africa was 9.88% (95% CI: 7.20-12.56) I<sup>2</sup>=97.9% and 23.04% (95% CI: 18.51-2757) I<sup>2</sup>=99.6%, respectively. In addition, the pooled prevalence of HBV and HCV co-infection was 7.18% (95% CI: 3.15-11.20) I<sup>2</sup>=99.6%. Duration of dialysis was found to be the contributing factor for the occurrence of HBV and HCV among HD patients (OR=1.44; 95% CI: 1.04, 2.01).</span></span></p> <p class="Default"><b>Conclusion</b></p> <p class="Default">This study showed that there is high prevalence of HBV and HCV infections in HD patients in Africa. Therefore, strict adherence to precautions of infection control measures, isolation of seropositive patients, improvement in infrastructures, adequate screening of HBV and HCV for the donated blood, and decentralized HD services is needed to minimize the risk of HBV and HCV infections in HD facilities.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.